Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2014-01-28 Regulatory Filings
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a 'Company release No 4/2014' dated January 28, 2014, announcing a positive recommendation from the FDA Advisory Committee regarding a drug (RAGWITEK™). This is a specific corporate event announcement related to regulatory progress and product development, not a comprehensive annual report (10-K), a quarterly report (IR), or a general earnings release (ER). It also explicitly mentions an upcoming 'Conference call' for analysts and investors, which often accompanies significant news. Since it is a specific, time-sensitive announcement of a material event (FDA advisory vote) that doesn't fit the other specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory/corporate update, or potentially an Earnings Release (ER) if it were tied to financial results, but here it is focused on regulatory progress. Given the options, RNS is the most appropriate fallback for a specific, non-financial-result-focused regulatory update that isn't a legal proceeding or management change.
2014-01-28 English
Report Publication Announcement 2014
Report Publication Announcement Classification · 98% confidence The document is a short announcement (1155 characters) in Danish stating that ALK will publish its Annual Report for 2013 on February 5, 2014, and will hold a conference call afterward. The key phrase is 'ALK offentliggør årsrapporten for 2013' (ALK publishes the annual report for 2013) and the subsequent details about the conference call and where the presentation will be available. According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report, especially when mentioning the associated presentation, should be classified as a Report Publication Announcement (RPA), not the report itself (10-K or AR).
2014-01-27 Danish
Report Publication Announcement 2014
Report Publication Announcement Classification · 98% confidence The document is titled "Selskabsmeddelelse nr. 3/2014" (Company Announcement no. 3/2014) and its subject is "Offentliggørelse af 2013 årsrapport og webcast" (Publication of the 2013 Annual Report and webcast). The text explicitly states that ALK will publish its 2013 annual report on February 5, 2014, and announces a subsequent conference call/webcast. Since the document itself is an announcement about the *publication* of the annual report, rather than the full 10-K report itself, and it is a regulatory announcement, it fits the definition of a Report Publication Announcement (RPA). The document length (1002 chars) is very short, supporting the RPA classification over the full Annual Report (10-K).
2014-01-27 English
Legal Proceedings Report 2014
Legal Proceedings Report Classification · 99% confidence The document is an announcement from ALK regarding the FDA posting briefing documents for an Advisory Committee meeting concerning a partner's (Merck's) Biologic License Application (BLA) for an allergy immunotherapy tablet. It details the meeting agenda, provides links to the FDA materials, and announces a subsequent conference call for analysts and investors. This document is not the full financial report (10-K or IR), nor is it a formal earnings release (ER) or a transcript (CT). It is an update concerning regulatory/legal proceedings related to product approval and partnership activities. Since it specifically discusses the FDA review process, advisory committee materials, and potential regulatory decisions, it most closely aligns with 'Legal Proceedings Report' (LTR) as it pertains to regulatory action/review, although it is also an investor update. Given the focus on the FDA review process and advisory committee input, LTR is the most appropriate fit among the specific categories, as it relates to regulatory/legal hurdles for a key product. It is not a general regulatory filing (RNS) because it is highly specific to a product review process.
2014-01-24 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a 'Company release No 2/2014' dated January 24, 2014. It announces that the FDA has posted briefing documents for an Advisory Committee meeting regarding a drug application (BLA) submitted by ALK's partner, Merck. The release details the purpose of the upcoming meeting, mentions the submission of the BLA, and announces a subsequent conference call for analysts and investors. Since the document's primary function is to inform the market about the availability of external regulatory materials (FDA briefing documents) and to announce a related investor call, it fits best as a general Regulatory Filing announcement or a Report Publication Announcement (RPA). Given the content is an announcement about regulatory activity and materials being made public, and it is not the full report itself, RPA is a strong candidate, but since it is a general regulatory update concerning FDA materials and includes a conference call announcement, it also aligns with the broader 'Regulatory Filings' (RNS) category if RPA is reserved strictly for company-issued reports. However, the core action is announcing the publication of external briefing documents and scheduling a call. The document is short (4271 chars) and announces external materials. I will classify this as a Regulatory Filing (RNS) as it is a general announcement regarding regulatory progress and materials availability, which is a common use case for RNS when a more specific code like ER or IR does not apply to the content itself.
2014-01-24 English
Earnings Release 2014
Earnings Release Classification · 95% confidence The document is titled "Selskabsmeddelelse nr. 1/2014" (Company Announcement no. 1/2014) and dated January 2, 2014. It discusses an update to German pricing regulations and its positive impact on ALK's expected revenue and earnings for 2014. Crucially, the text states: "ALK vil præcisere forventningerne til 2014 i årsrapporten for 2013, der udsendes den 5. februar 2014" (ALK will clarify the expectations for 2014 in the annual report for 2013, which will be issued on February 5, 2014). This indicates the current document is an announcement providing preliminary guidance or an update, not the full Annual Report (10-K) or the subsequent Earnings Release (ER). Since it is a formal company announcement regarding financial outlook/expectations, it fits best under the general category of Regulatory Filings (RNS) or potentially an Earnings Release (ER) if it were the primary results announcement. Given that it is an update *before* the official report release date and is structured as a formal company announcement ('Selskabsmeddelelse'), RNS is the most appropriate general regulatory filing category, as it is not a transcript (CT), management discussion (MDA), or the full annual report (10-K). However, because it explicitly discusses financial expectations/outlook, it is closely related to an Earnings Release (ER). Since ER is defined as the *initial announcement of periodical financial results (key highlights only)*, and this document provides key highlights (financial impact of the German reform) and sets the stage for the full report, ER is a strong candidate. Given the context of providing financial outlook updates outside of the formal quarterly/annual release structure, RNS (Regulatory Filings) serves as the safest catch-all for non-standard, yet material, announcements. I will classify it as RNS as it is a general regulatory announcement updating market expectations. FY 2014
2014-01-02 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.